Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | CD44 | P16070 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indoline SCHEMBL5629 | 0.93 | — | — | |
| Indoline SCHEMBL29360339 | 0.93 | — | — | |
| Indoline SCHEMBL11570171 | 0.91 | HTR2C (0.46) | DRD2DRD4HTR2CPDPK1PARP1 | |
| Indoline SCHEMBL27584027 | 0.91 | HTR2C (0.46) | DRD2DRD4HTR2CPDPK1PARP1 | |
| Indoline SCHEMBL23295083 | 0.91 | HTR2C (0.50) | DRD2DRD4HTR2CPDPK1PARP1 | |
| Indoline SCHEMBL10723456 | 0.91 | HTR2C (0.50) | DRD2DRD4HTR2CPDPK1PARP1 | |
| Indoline SCHEMBL1587228 | 0.91 | HTR2C (0.50) | DRD2DRD4HTR2CPDPK1PARP1 | |
| Indoline SCHEMBL8194348 | 0.91 | HTR2C (0.50) | DRD2DRD4HTR2CPDPK1PARP1 | |
| Indoline SCHEMBL1085136 | 0.91 | HTR2C (0.50) | DRD2DRD4HTR2CPDPK1PARP1 | |
| Indoline SCHEMBL8297156 | 0.91 | HTR2C (0.50) | DRD2DRD4HTR2CPDPK1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318997-A1 | NOVEL 4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND THERAPEUTIC USE THEREOF | AMR TECHNOLOGY, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| CN-100430401-C | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof | ALBANY MOLECULE RES INC (US) | 2008-11-05 | — | — | CN | disclosed |
| US-7419985-B2 | 4-Phenyl substituted tetrahydroisoquinolines and therapeutic use thereof | AMR TECHNOLOGY, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7309789-B2 | 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof | AMR TECHNOLOGY, INC. (US) | 2007-12-18 | — | — | US | disclosed |
| US-20060217409-A1 | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof | AMR TECHNOLOGY, INC. (US) | 2006-09-28 | — | — | US | disclosed |
| US-7084152-B2 | 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof | AMR TECHNOLOGY, INC. (US) | 2006-08-01 | — | — | US | disclosed |
| WO-2006057955-A2 | NOVEL 4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND THERAPEUTIC USE THEREOF | AMR TECHNOLOGY, INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| US-20060111385-A1 | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof | ALBANY MOLECULAR RESEARCH, INC. | 2006-05-25 | — | — | US | disclosed |
| US-20060111386-A1 | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof | AMR TECHNOLOGY, INC. (US) | 2006-05-25 | — | — | US | disclosed |
| US-20060025435-A1 | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof | AMR TECHNOLOGY, INC. (US) | 2006-02-02 | — | — | US | disclosed |
| CN-1452623-A | 4-phenyl substd. tetrahydroisoquinolines and therapeutic use thereof | ALBANY MOLECULE RES INC (US) | 2003-10-29 | — | — | CN | disclosed |
| EP-1299393-A2 | 4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND THERAPEUTIC USE THEREOF | Bristol-Myers Squibb Pharma Company (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20020091134-A1 | Novel 4-phenyl substituted tetrahydroiso quinolines therapeutic use thereof | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2002-07-11 | — | — | US | disclosed |
| WO-2002004455-A2 | 4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND THERAPEUTIC USE THEREOF | ALBANY MOLECULAR RESEARCH, INC (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111386-A1 | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof | HTR2C, HTR3B, HTR2B | DRD2 35/4885DRD4 148/4885HTR2C 1/4885 |
| US-20060217409-A1 | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof | GRIN2C, HTR3B, HTR2C | DRD2 38/4885DRD4 54/4885HTR2C 3/4885 |
| US-20060111385-A1 | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof | HTR2C, HTR3B, HTR2B | DRD2 35/4885DRD4 148/4885HTR2C 1/4885 |
| US-20080318997-A1 | NOVEL 4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND THERAPEUTIC USE THEREOF | GRIN2C, HTR3B, HTR2C | DRD2 38/4885DRD4 54/4885HTR2C 3/4885 |
| US-20020091134-A1 | Novel 4-phenyl substituted tetrahydroiso quinolines therapeutic use thereof | HTR3B, GRIN2C, HTR2B | DRD2 53/4885DRD4 67/4885HTR2C 4/4885 |
| US-20060025435-A1 | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof | GRIN2C, HTR3B, HTR2C | DRD2 38/4885DRD4 54/4885HTR2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.